Nova Eye Medical Ltd
AASX:EYE0.16
AUD
+0.01
(+6.90%)
ISIN
AU0000094252
Return %
Stock
S&P 500
1Y
-3.12
14.20
3Y
-24.20
81.12
5Y
-61.18
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Thomas Spurling
- Full Time Employees
- 301
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 107 Rundle Street Kent Town SA Australia 5067
- IPO Date
- Oct 12, 1987
- Website
- nova-eye.com
- Similar Companies
- Business
- Nova Eye Medical Limited designs, develops, manufactures, markets and sells proprietary surgical devices and technologies primarily for glaucoma treatment and related ophthalmic conditions. The company offers the iTrack family of canaloplasty microcatheters, including iTrack and iTrack Advance, which restore the eye's natural outflow pathway to reduce intraocular pressure in patients with mild to moderate open-angle glaucoma without stents or tissue removal; the Molteno3 glaucoma drainage device platform for severe and complex glaucoma cases, providing simplified surgical procedures and long-term intraocular pressure control; and the 2RT laser technology for early and intermediate age-related macular degeneration and diabetic retinopathy. Incorporated in 1970 and headquartered at 107 Rundle Street in Kent Town, South Australia, Nova Eye Medical operates sales headquarters in Fremont, California, with manufacturing facilities in Fremont and Dunedin, New Zealand, and serves eye surgeons in over 100 countries across the United States, Europe, Asia Pacific including China, Australia and other international markets through direct sales teams and a global network of distribution partners. Formerly known as Ellex Medical Lasers Limited, the company changed its name to Nova Eye Medical Limited in July 2020 following the divestment of its lasers and ultrasound business to Lumibird Group SA in June 2020. Recent developments include National Medical Products Administration approval for iTrack Advance in China in September 2025 to expand sales in that market; global sales excluding China of US$4.9 million in the quarter ended September 2025, up 32% year-over-year, with last 12 months revenue exceeding A$30 million; reaffirmed FY26 sales guidance excluding China of US$21-24 million and expectation of EBITDA breakeven in the second half of FY26; a A$488,000 grant award in July 2025 with Adelaide University for quantum technology in early eye disease detection; and ongoing evaluation of iTrack microcatheter for targeted ocular drug delivery with pharmaceutical partners.